Tannaz Moin|Jinnan Li|O. Kenrik Duru|Susan L. Ettner|Norman Turk|Abigail M Keckhafer|Sam Ho|Carol M. Mangione
Metformin Prescription for Insured Adults With Prediabetes From 2010 to 2012
Health Services Research & Development|University of California, Los Angeles|Health Services Research & Development|University of California, Los Angeles|Health Services Research & Development|University of California, Los Angeles|Health Services Research & Development|University of California, Los Angeles|Health Services Research & Development|University of California, Los Angeles|Health Services Research & Development|University of California, Los Angeles|Health Services Research & Development|University of California, Los Angeles|Health Services Research & Development|University of California, Los Angeles
background prediabetes affects 1 3 americans intensive lifestyle intervention metformin prevent delay progression diabetes past decade lifestyle interventions translated across various settings little known translation evidence surrounding metformin use objective examine metformin prescription diabetes prevention patient characteristics may affect metformin prescription design retrospective cohort analysis 3year period setting employer groups purchased health plans nations largest private insurer participants national sample 17 352 workingage adults prediabetes insured 3 continuous years 2010 2012 measurements percentage health plan enrollees prediabetes prescribed metformin results 37 patients prediabetes prescribed metformin 3year study window adjustment age income education predicted probability metformin prescription almost 2 times higher among women obese patients 15 times higher among patients 2 comorbid conditions limitation missing data lifestyle interventions possible misclassification prediabetes metformin use inability define eligible patients exactly defined american diabetes association guidelines conclusion evidence shows metformin rarely prescribed diabetes prevention workingage adults future studies needed understand potential barriers wider adoption safe tolerable evidencebased costeffective prediabetes therapy primary funding source centers disease control prevention division diabetes translation national institute diabetes digestive kidney diseases